Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people with ...

Teleneurorehabilitation provides similar improvement in motor and nonmotor symptoms for patients with Parkinson’s disease as ...

Mar. 9, 2025 — A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells ...

Idiopathic REM sleep behaviour disorder (iRBD) causes people to physically act out their dreams while sleeping. The disorder is also associated with a very high risk of Parkinson's disease and a ...

For people with a certain sleep disorder, a simple blood test could help predict the development of dementia years before symptoms appear, a new study indicates. Idiopathic REM sleep behavior disorder ...

The research findings primarily focus on individuals with a sleep disorder but may have broader implications. A recent study ...

Interim Analysis Expected End of 2Q 2025 BETHESDA, MD / ACCESS Newswire / March 14, 2025 / Gain Therapeutics, Inc. (Nasdaq:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company lead ...

Researchers at McGill University found that a blood test originally designed for Alzheimer’s can predict dementia risk in ...

Gain Therapeutics (GANX) announced the dosing of the first participant with Parkinson’s disease in its Phase 1b clinical trial of GT-02287, the ...

“Whether they are living with the disease or caring for someone impacted by it, Parkinson’s takes a terrible toll ... the first FDA-approved therapy for idiopathic macular telangiectasia ...